Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 25, Issue 3, Pages 273-284Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14728214.2020.1801632
Keywords
Pruritus; chronic itch; clinical trials; monoclonal antibodies; biologics; small molecule agents; JAK inhibitors
Categories
Ask authors/readers for more resources
Introduction Chronic pruritus is non-histaminergic and mediated through a complex interplay of peripheral and central immune and neural pathways. Significant developments in the understanding of chronic pruritus have emerged and paved the way for new, emerging therapies. Areas covered This review details the emerging drug landscape for chronic pruritus treatment, focusing on monoclonal antibody agents that target key cytokines and their receptors as well as small molecule agents that inhibit mediators of the immune and neural pathways. The article provides background regarding the currently available therapies and the rationale for the development of new agents based on the current market and recent scientific developments. Expert opinion Identification of new targets along neuroimmune itch pathways has allowed for the development of targeted drugs which can be utilized for effective therapy. As we enter a new era of chronic itch treatments, we face exciting prospects and challenges.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available